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Summary
Background Chronic neuropathic pain in leprosy patients after completion of
multi-drug therapy (MDT) is an under-researched problem. The reason why some
leprosy patients develop it is unknown. In this study we evaluated the role of
ongoing inflammation and small-fibre neuropathy as possible contributing factors for
neuropathic pain.
Methods We assessed chronic neuropathic pain in 17 leprosy patients who had
completed MDT and were attending a referral clinic in Hyderabad, India. All patients
had a clinical assessment, intraepidermal nerve (IENF) assessment and quantitative
sensory testing (QST), which included the testing of tactile and pinprick sensations
using Semmes–Weinstein monofilaments and weighted needles method. Nine
patients had a sural nerve biopsy (SNB).
Results Thirteen patients had a glove and stocking pattern of neuropathy. All nerve
biopsies showed inflammation with intraneural inflammation and perineural
†These authors contributed the manuscript equally and thus share the first authorship.
Correspondence to: Aki Heitaharju, Department of Neurology, Tampere University Hospital, PO Box 2000,
33521 Tampere, Finland (e-mail: Aki.Hietaharju@pshp.fi)
Lepr Rev (2007) 78, 369–380
0305-7518//064053+12 $1.00 q Lepra 369
thickening, and intraneural acid fast bacilli were observed in five biopsies. IENF
analysis of the skin biopsy specimens in 16/17 patients showed a statistically
significant reduction in IENF density (P , 0·001, Mann Whitney test) compared to
control skin biopsies. Complete depletion of intraepidermal nerves was observed in
six patients. QST also showed marked abnormalities. In 11 patients total sensory loss
for all modalities was found, and in the other six patients the sensory function was
seriously impaired.
Discussion There is evidence of ongoing intraneural inflammation in leprosy
patients who have completed MDT. This may explain the occurrence of chronic
neuropathic pain. Using IENF density measurement we have found significant small-
fibre neuropathy in leprosy patients and the use of this tool could be expanded.
Introduction
Neuropathic pain is a pain condition initiated or caused by a primary lesion or dysfunction in
the nervous system.1 Paradoxically, although leprosy is classically associated with anesthesia
affecting the hands and feet, neuropathic pain may become a problem for some patients.
Leprosy-related pain can be moderate or severe and occur either continuously or
intermittently. It can occur in patients who have completed multi-drug therapy (MDT).2
It is not known why some leprosy patients develop chronic neuropathic pain. One
explanation is the pathological involvement of small nerve fibres. These nerve fibres are of
small calibre and normally responsible for sensation of heat and pain. It has been suggested
that in early leprosy, pain and temperature sensation are diminished first, followed later by
loss of tactile and pressure senses.3 This pattern of sensory loss suggests early involvement of
small fibres due to inflammation secondary to mycobacterial invasion of the Schwann cells.
Small-neuropathy (SFN) is defined on physiological or anatomical terms as a sensory
neuropathy that exclusively or predominantly affects small fibres and their functions. Painful
paresthesias are the commonest symptoms of both acquired and idiopathic small-fibre
neuropathy.4 However, experienced observers have disagreed on the precise sequence of
sensory loss by modalities. According to Cochrane, the order of loss is first thermal, then
tactile, followed by pain and ultimately pressure sense.5
Intraepidermal nerve fibre (IENF) density determination by using punch skin biopsies is a
useful diagnostic test for patients with suspected SFN.6 The most frequently reported
abnormality in neuropathies affecting epidermal innervation is a reduction in nerve fibre
numbers. In addition to SFN, the alteration of IENF may also be useful in assessing the course
and spatial distribution of nerve injury in other peripheral neuropathies. Significant reduction
in intraepidermal fibres has been demonstrated for example in patients with HIV-related
sensory neuropathy.7 Different methods are available for the epidermal nerve fibre analysis.
The most sophisticated protocols include the use of confocal microscopy and imaging
software, but the counting of epidermal fibres can also be performed using conventional
microscopy. Common for all these methods is the use of immunohistochemistry with a
protein gene product 9·5 (PGP 9·5) antibody. PGP 9·5 is a neuron-specific ubiquitin
hydrolase, which is present in all axons, including the unmyelinated nerve endings and the
epidermal nerve fibres.8 Hence, it serves as a tool for investigation of cutaneous innervation
and axonal degeneration in peripheral neuropathies. According to the studies, quantitation of
epidermal nerves has a diagnostic efficiency of 88% for patients with sensory neuropathies.4
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The objectives of this study were: 1) to document the parameters of neuropathic pain in
leprosy patients who have completed their antimicrobial therapy, 2) to determine if leprosy
patients with chronic neuropathic pain have peripheral neuropathy involving unmyelinated
and small myelinated nerve fibres, 3) to explore the relationship between loss of cutaneous
innervation and pain in these patients, and 4) to compare the findings of intraepidermal nerve
analysis and sural nerve biopsy in different types of leprosy patients.
Materials and methods
CASE DEFINITIONS AND EXCLUSIONS
Patients who had completed antimicrobial treatment and were complaining of pain and
dysesthesia were recruited at the Blue Peter Research Centre in Hyderabad, India. Of these
patients, only those with neuropathic pain lasting at least 6 months and scoring current pain
intensity $4/10 by 11-point Likert scale were included in the study. The patient intake
covered the spring of 2003. The diagnosis of leprosy was made clinically and supported
histologically with patients classified according to the Ridley-Jopling scale.9 Exclusion
criteria included treatment with thalidomide or other neurotoxic drugs, known HIV infection,
hereditary neuropathy, central nervous system disease, diabetes (screening with urine glucose
test), hypothyroidism (screening with blood TSH levels), known thiamine or B12 deficiency,
or a history of alcohol abuse. Patients with concomitant nociceptive pain condition (i.e. joint
disease, painful ulcers, osteomyelitis) that might have complicated the pain analysis were
also excluded.
CLINICAL ASSESSMENT AND QUANTITATIVE SENSORY TESTING
The location of pain was recorded by using pain drawings10 (Figure 1).
Patients were asked about the type(s) of their pain (constant or intermittent lancinating pain),
and the presence of paresthesia and dysesthesia. The intensity of the various pain components and
dysesthesia was assessed with verbal rating scale (mild, moderate, severe) and with 11-point
Likert scale (0–10).10 The interference of sleep due to the pain was evaluated with 11-point
Likert scale. Thickness of individual nerves was evaluated and recorded as normal or thickened.
Tenderness of the nerves was recorded if it was present also when the patient’s attention was
distracted or if the patient withdrew the limb while the nerve was palpated.
Sensory testing was performed assessing heat, cold, tactile, and pinprick sensation. The
presence and type of mechanical allodynia (dynamic and static) was assessed. Sensations
were graded as normal (unaltered), anesthethetic, hypoesthethetic or hyperesthetic. Heat
sensation was examined with the Thermal Sensation Tester; B.S. Tech, Switzerland (TST)
using a study temperature ofþ50 8C. Cold sensation was tested using a glass bottle filled with
water, which had been kept in the refrigerator (þ4 8C). Tactile and pinprick sensations were
evaluated both qualitatively and quantitatively, the former using Semmes–Weinstein
monofilaments11 and the latter using weighted needles method.12 The testing sites for
quantitative tactile and pinprick testing were in the leg, ankle, knee and hip, and in the arm,
wrist, elbow and shoulder and the sites of pain sensation. The weighted needle apparatus
consisted of 12 weighted 23 gauge disposable needles (0·2–5·2 g). The dynamic type of
mechanical allodynia was assessed using a paint brush used in water colour painting and the
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static type of mechanical allodynia was assessed by light compression. The terms of sensory
dysfunction are explained in Table 1.
PUNCH BIOPSIES AND THEIR HISTOLOGY AND IMMUNOHISTOCHEMISTRY
A punch skin biopsy was taken from all subjects on the distal leg 10 cm above the lateral
malleolus. After local infiltration of 1% xylocaine, 3 mm punch biopsy was taken with
appropriate asepsis and a dressing applied. Control skin biopsies were taken from the surgical
margins of seven healthy people (2 males and 5 females; age range 4–68, mean 42) having a
benign nevus at Tampere University Hospital, Finland. None of the controls had a known
neurological disease, diabetes, a history of alcohol abuse or use of any neurotoxic drugs (data
from hospital patient records).
Specimens were fixed in 10% formalin for 4 days and then embedded in paraffin. Ten-mm
sections were cut on ChemMateTM capillary gap microscope slides (Dako Cytomation
Figure 1. An example of pain drawing.
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Denmark a/s, Glostrup, Denmark). Rehydrated sections were heated in a microwave oven at
850 W for two 7-minute cycles using 0·01 mol/l citrate buffer (pH 6·0) as antigen retrieval
solution. For demonstration of terminal axons, a polyclonal panaxonal marker PGP 9·5
(ubiquitin hydrolase, Ultraclone, Isle of Wight, UK) was used at dilution 1:20. The
immunohistochemical staining was performed using indirect streptavidin-biotin-peroxidase
method in ChemMateTM 500 Immunostainer (Dako Cytomation Denmark). In negative
controls primary antibody was omitted or replaced by irrelevant antisera.
The number of separate IENF was counted with a light microscope at 400x magnification
by an independent observer (MK) blinded to the clinical status of the patients. The counting
method has been described in previous studies.13
NERVE BIOPSY
Partial thickness sural nerve biopsy was taken from the ankle using standard techniques.
Specimens were examined by an experienced pathologist (SS) looking for evidence of a)
chronic neuritis, b) vasculitis, c) fibrosis, d) acid fast bacilli and/or debris, e) loss of small
myelinated and/or unmyelinated axons. Teased fibre analysis was used in identifying
pathologic conditions denoting demyelination and axonal degeneration.
STATISTICAL ANALYSIS
Statistical analysis was performed using SPSS for Windows version 11.0 software (SPSS
Inc., Chicago, IL, USA). For each subject, IENF density was plotted against clinical
symptoms. The effect of age, gender and type of leprosy on the IENF density was examined
in all subjects. The concordance between the IENF and nerve biopsy was examined in 11
subjects. Difference in the number of intraepidermal nerve fibres between the groups was
assessed using Mann–Whitney U and Kruskall Wallis test.
ETHICAL CONSIDERATIONS
The study protocol was approved by the local ethical committee of The Blue Peter Research
Centre, Hyderabad. Patients were informed in detail about the possible consequences of
the sural nerve biopsy (risk of infection, mild sensory abnormalities) and then invited to
give written informed consent. The study was in accordance with the Helsinki Declaration
of 1975.
Table 1. The terms of sensory dysfunction
Paraesthesia An abnormal sensation, whether spontaneous or evoked
Dysaesthesia An unpleasant abnormal sensation, whether spontaneous or evoked
Allodynia Pain due to a stimulus, which does not normally provoke pain;
divided into mechanical and thermal subtypes
Hyperalgesia An increased response to a stimulus which is normally painful
Hypoalgesia Diminished pain in response to a normally painful stimuli
Hyperesthesia Increased sensitivity to stimulation, excluding the special senses
Hypoesthesia Decreased sensitivity to stimulation, excluding the special senses
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Results
PATIENTS
The demographic data of the patients and subtypes of leprosy are presented in Table 2.
The age range of patients was 27–69, mean 46 years. The mean time since released from
therapy was four years (range 0·5–11·5 years). Nine patients had a previous history
of corticosteroid use due to reactions or neuritis (mean cumulative dose 4624 mg, range
750–11250 mg). Seven patients had experienced Type I reactions (n 1–4; mean 2). Two
patients had experienced type II reactions.
CHARACTERISTICS OF NEUROPATHIC PAIN
The distribution, duration and severity of pain are presented in Table 2. Pain was located in
the extremities for all patients, but four patients also had burning facial pain. Pain was
continuous in 15 patients, whereas one patient had episodic pain and another patient had
disturbing dysesthesia. Pain was burning in all patients, and none had lancinating pain. In two
patients the movement of a limb or an exercise caused exacerbation of pain.
The intensity of pain varied from 4 to 10 on Likert scale (mean 6·4), and pain was graded
as severe by nine, moderate by four and mild by four patients. In addition to pain, one patient
had touch-evoked paresthesia and 16 patients reported spontaneous paresthesia which was
graded as severe by seven, moderate by five and mild by five patients. Nocturnal awakenings
due to pain were reported by 15 patients, and sleep interference varied between 3 and 10 on
Likert scale (mean 7·1). Continuous pain medication was used by 16 patients; 15 patients
used acetylsalicylic acid and one used paracetamol.
CLINICAL EXAMINATION AND QUANTITATIVE SENSORY TESTING
Findings in nerve palpation and quantitative tactile testing are presented in Table 2. All
patients had more than one tender nerve on palpation (range 2–15). Pain in a glove and
stocking distribution was the commonest, seen in 71% (n ¼ 12) of patients. These patients
also had corresponding sensory loss for all tested modalities in 11 cases and well preserved
sensory function in one case (patient number 5). Patients with pain located in a territory of
one or several nerves had sensory loss in corresponding area, but in 12 cases, a more wide-
spread sensory loss was noticed. None of the patients had hyperalgesia or allodynia. Tendon
reflexes were found to be normal in all patients. In the sensory assessment with weighted
needles for pinprick sensation, eight patients did not detect any of the 12 needles in any
testing site while four had well preserved sensory function (detection level below 0·65 g).
The remaining five patients had diminished pinprick sensation predominantly in lower
extremities.
BIOPSIES
Sections of the skin biopsies immunostained with a polyclonal antibody to PGP 9·5 revealed
the separate IENFs and their location within the tissue. In positive control specimens, a large
number of fine IENFs with good preservation of axonal morphology were found. For
the analysis, the patients were divided into two groups according to their clinical findings.
The first group (n ¼ 12) comprised of patients with stocking and glove polyneuropathy, the
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Table 2. Clinical characteristics and histological findings in 17 patients with leprosy and neuropathic pain. The patients are ordered by the distribution of pain and the type of
leprosy in each group
Pat.nr
Age/
gender Type of leprosy
Time since
RFT (y)
Distribution
of pain
Duration
of pain (y)
Severity
of pain Bacilli site
Number
of tender
nerves
TT
(left)
TT
(right)
Nerves per
epider-
mal area
Inflamma-
tion in
nerve biopsy Reactions CC (mg)
1 53/F BT 2·5 Glove and stocking 0·5 Mild – 3 SL SL 0 n.p. 0 0
2 33/F BT 1·5 Glove and stocking 4 Severe No bacilli
seen
7 SL SL 0 Moderate 1 £ type I 3850
3 58/M BT Not
known
Glove and stocking 2 Mild Intraneural 9 3·84 4·31 3·59 Moderate 0 Not known
4 46/M BT 10·5 Glove and stocking 10 Severe – 6 SL SL 0 n.p. 0 0
5 38/F BT 3 Glove and stocking 2·5 Moderate Intraneural 9 2·36 2·44 90 Mild 2 £ type I 4465
6 41/F BT 0·5 Great toes 0·5 Mild – 3 4·17 4·56 25·81 n.p. 1 £ type I 1125
7 44/M BT 1·5 Soles, great toes 5 Severe No bacilli
seen
6 SL SL 24·06 Intraneural 1 £ type I 0
8 56/M BT 1·5 Medial side of feet 4 Severe No bacilli
seen
9 4·08 3·61 37·5 Mild 3 £ type I 4650
9 29/M BT 3 Soles, V fingers 2 Mild – 7 2·83 3·61 4·16 n.p. 0 4500
10 51/M BL 2·5 Left sole 3 Moderate – 2 SL SL 3·46 n.p. 0 0
11 36/F BL 0·5 Glove and stocking 2 Severe – 3 SL SL 4·95 n.p. 1 £ type I 1125
12 27/M BL 3 Glove and stocking 3 Severe – 6 SL SL 0 n.p. 4 £ type I 9900
13 68/M BL 7·5 Glove and stocking 4 Severe – 7 SL SL 9·64 n.p. 0 0
14 69/M BL 11·5 Glove and stocking 2 Moderate Intraneural 5 SL SL 0 Moderate 0 0
15 38/F LL 1 Glove and stocking 2 Severe Intraneural 15 SL SL 0 Moderate 1 £ type II 750
16 48/F LL 3·5 Glove and stocking 4·5 Moderate Intraneural 9 SL SL 8·21 Moderate 0 0
17 43/F LL 7·5 Glove and stocking 0·5 Severe No bacilli
seen
7 3·84 3·84 5·76 Mild 5 £ type II 11250
RFT, released from treatment; n.p., nerve biopsy not performed; TT, tactile threshold at the dorsum of feet (number corresponds to a logarithmic function of the equivalent
forces, grams); SL, sensory loss; CC, cumulative amount of corticosteroids.
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second group (n ¼ 5) of patients with mononeuropathy or multiple mononeuropathy. The
IENFs were significantly better preserved in controls than in either patient group (P , 0·001,
Mann–Whitney test). When the two groups of patients were compared, significantly less
IENFs were present in the glove and stocking group (P ¼ 0·03). In this group, almost a total
absence of IENFs was noticed in skin specimens of 11 patients, while IENFs were well
preserved in one case (patient number 5 who had pain only in her palms and soles). IENF
densities of all patients and controls are compiled in Figure 2.
Figure 2.
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No correlation was found between the IENF counts and patient age or gender (P ¼ 0·678,
P ¼ 0·984, respectively). There was, however, a statistically significant negative correlation
between the IENF count and the number of type I or type II reactions (P , 0·001, ANOVA):
the more reactions patients had the fewer IENFs were found in skin specimens. There was
also a growing tendency of patients with recurring reactions to experience more severe pain,
even though the statistical significance was not reached (P ¼ 0·72).
A sural nerve biopsy was performed in nine patients, all of whom had palpably thickened
nerves. There was clear evidence of inflammation in nine nerve biopsy specimens. In eight
biopsy specimens the perineurium was thickened while in one there was inflammation and
lamination of the perineurium indicating ongoing intraneural inflammation. Scanty acid-fast
bacilli were detected in five biopsy specimens. In two cases inflammatory activity was found
even in the nerves with abundant co-existing fibrosis. Lymphocytes were the predominant
inflammatory cell type in seven biopsy specimens. In this study with a limited number of
patients, no statistical significances were found in the nerve biopsy findings between the
different subgroups of leprosy. The amount of inflammation seen in the nerves did not
correlate with IENF numbers.
Discussion
This study corroborated previous findings of the existence of chronic disturbing neuropathic
pain in a subgroup of treated leprosy patients.2,14 Pain was predominantly of continuous
burning type; lancinating pain was absent. Glove and stocking distribution was most common
in our patients. In addition to pain, paresthesia was prevalent, and the intensity of these two
symptoms was in concordance in most cases. Sleep was interrupted due to pain, and most
patients used pain medications regularly. However, there are no controlled studies on the
efficacy of simple analgesics on chronic neuropathic pain. The choice of treatment in these
patients reflects the local availability, cost and awareness of pharmacotherapy of neuropathic
pain. Tricyclic antidepressants and several antiepileptic drugs have good evidence of efficacy
in various neuropathic pain states,15 but to date there are no studies of their use in leprosy-
related neuropathic pain.16
In our patients, no signs of hyperalgesia or allodynia were found. The possible
explanation could be silent inflammation and slow but complete destruction of nerves. It has
been suggested that hyperalgesia and allodynia are typical in states with well preserved and
irritated peripheral sensory fibres which are overactive and cause central sensitisation.17 In
diseases such as leprosy, with profound loss of peripheral nerve fibres, allodynia caused by
overactive peripheral fibres is an unlikely phenomenon.
PGP 9·5 immunostaining of skin biopsies has been used to quantify IENF density and its
alterations to document the presence of peripheral neuropathy.18,19 Previous studies have
demonstrated the usefulness of cutaneous nerve evaluation in SFN of various origins.20,13 The
existence of SFN in leprosy patients has previously been shown21,22 but until now it has not
been demonstrated histopathologically using IENF assessment. The skin biopsies were taken
from standard sites, i.e. ankle, because the reference values have not been published from
other parts of the body. In forthcoming studies punch biopsies may be needed to take both
from the painful area and the standard location.
One of the possible reasons for pain in treated leprosy patients could be an ongoing
chronic inflammation in and around the nerves. Inflammation along nerve trunks has been
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shown to produce ectopic activity in nerves. This may lead to prolonged afferent barrage to
the dorsal horn causing central sensitisation, and finally chronic neuropathic pain.23 It is
noteworthy that most of our patients had some nerve tenderness and that the nerve biopsies
showed evidence of ongoing inflammation. Further studies should investigate the molecular
mechanisms underlying this ongoing inflammation and cellular activation. It is possible that
M. leprae antigens persist in nerves, possibly inside Schwann cells and that these are being
presented to the immune system. A previous study on nerve biopsies from leprosy patients
with Type I reactions showed that M. leprae antigens were detectable in reactional nerves.24
These data reinforce the observation that clinical and pathological processes can occur in
leprosy patients long after multi-drug therapy. In a few patients, vasculitis of the small
epineural vessels, precipitated by persisting mycobacterial antigen, may lead to ischemic
injury of the nerves and cause painful neuropathy.25 In our patients, none had evidence of
vasculitis in sural nerve biopsy specimens.
In addition to present inflammatory conditions, the burden of past episodes of neuritis
may be a source of pathologic and aberrant activity of peripheral nerves.26 It has been shown
that cytokine production near the site of nerve injury is critical to the development and
maintenance of central sensitisation and neuropathic pain.27
Acid fast bacilli were detected in five nerve biopsies. Patients had completed MDT from 1
to 11·5 years previously. This raises the possibility that even in this small set of patients with
nerve pathology bacteria are persisting in the nerve. We have no way of knowing whether
these bacilli were viable. We also do not know whether the patients were compliant with their
treatment. For patients treated many years previously re-infection is a possibility. However,
Shetty et al. have shown that M. leprae can be recovered from the nerves of patients who have
been treated with MDT.28 Porichha has also shown that in patients with post-treatment
neuritis there is evidence of active disease.29 This emphasises the long-term pathology
occurring in the nerves of leprosy patients.
There are some important methodological limitations in our study. Firstly, there was no
suitable control group. Including a control group with patients who did not have neuropathic
pain and who were matched for the type and duration of leprosy would have given valuable
information on the role of SFN in leprosy-related painful neuropathy. Secondly, control skin
biopsies were taken from Finnish patients. Even though the differences in IENF density in
healthy individuals are unlikely among ethnic groups, it would have been appropriate to
include an Indian control group. Thirdly, tools used in the assessment of thermal sensation
were not validated. The Swiss Thermal Sensation Tester has been widely distributed among
leprosy field workers but there is no available data on its validation.
Despite the limitations, we found clear evidence of ongoing inflammation in biopsy
specimens of treated leprosy patients. In these patients an obvious SFN due to leprosy was
also verified histopathologically. A larger cross-sectional study of a population of treated
patients with an appropriate control group is needed to define the extent of the problem. It
would also enable the identification of possible pathophysiological mechanisms more
accurately. It is presumable that the mechanisms of neuropathic pain vary between subtypes
of leprosy. A larger study would also be able to address other important issues such as the
impact that ongoing neuropathic pain has on the quality of life of these patients and whether it
causes depression. Further studies are also needed to develop protocols for the management
of neuropathic pain.
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